Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H27FO5 |
| Molecular Weight | 390.4452 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC(=C)[C@]2(O)C(=O)CO
InChI
InChIKey=YVHXHNGGPURVOS-SBTDHBFYSA-N
InChI=1S/C22H27FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,15-17,24,26,28H,1,4-5,8,10-11H2,2-3H3/t15-,16-,17-,19-,20-,21-,22-/m0/s1
| Molecular Formula | C22H27FO5 |
| Molecular Weight | 390.4452 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.pharmazie.com/graphic/A/49/0-14349.pdf
Sources: http://www.pharmazie.com/graphic/A/49/0-14349.pdf
Fluprednidene (used in a form of fluprednidene 21-acetate) is a glucocorticoid developed for the treatment of inflammatory skin diseases. The drug is marketed under the name Decoderm in Europe.
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
0.1 % single, topical Recommended Dose: 0.1 % Route: topical Route: single Dose: 0.1 % Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Hypersensitivity... AEs leading to discontinuation/dose reduction: Hypersensitivity Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Hypersensitivity | Disc. AE | 0.1 % single, topical Recommended Dose: 0.1 % Route: topical Route: single Dose: 0.1 % Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Double-blind comparison of miconazole/corticosteroid combination versus miconazole in inflammatory dermatomycoses. | 1995-02 |
|
| Dermal absorption of fluprednidene-21-acetate and miconazole from a new topical preparation in pigs. | 1994-11 |
|
| [Optimized interval treatment of eczema with fluprednidene. A multicenter double-blind study]. | 1989-09-15 |
|
| Steroid-induced dermal atrophy. Investigations on discontinuous application. | 1989 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.pharmazie.com/graphic/A/49/0-14349.pdf
Apply the cream to the affected skin areas once a day.
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:32:58 GMT 2025
by
admin
on
Mon Mar 31 18:32:58 GMT 2025
|
| Record UNII |
FA517NS3N7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
D07CB02
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
||
|
WHO-ATC |
D07XB03
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
||
|
WHO-VATC |
QD07XB03
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
||
|
WHO-VATC |
QD07CB02
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
||
|
NCI_THESAURUS |
C521
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
||
|
WHO-ATC |
D07AB07
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
||
|
WHO-VATC |
QD07AB07
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
236650
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
PRIMARY | RxNorm | ||
|
CHEMBL2106763
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
PRIMARY | |||
|
218-591-0
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
PRIMARY | |||
|
2193-87-5
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
PRIMARY | |||
|
FA517NS3N7
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
PRIMARY | |||
|
DB08970
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
PRIMARY | |||
|
Fluprednidene
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
PRIMARY | |||
|
4553
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
PRIMARY | |||
|
C77421
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
PRIMARY | |||
|
DTXSID30176343
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
PRIMARY | |||
|
SUB07735MIG
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
PRIMARY | |||
|
2450
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
PRIMARY | |||
|
11794741
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
PRIMARY | |||
|
100000080722
Created by
admin on Mon Mar 31 18:32:58 GMT 2025 , Edited by admin on Mon Mar 31 18:32:58 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |